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Abstract  
Autism Spectrum Disorders (ASDs) are neurodevelopmental 
syndromes, in which several environmental risk factors act on 
a vulnerable genetic background. Among genes whose 
mutations have been associated with ASDs, the R451C 
substitution in the synaptic protein Neuroligin3 (NLGN3) has 
been highly characterized. 
It is known from in vitro studies, that the mutation affects 
folding of the extracellular domain of the protein, causing its 
retention in the Endoplasmic Reticulum (ER) and the 
activation of the Unfolded Protein Response (UPR). It has 
been shown both in vitro and in vivo, that only ~10% of the 
mutant protein reach the synapse, causing loss of NLGN3 on 
the cell surface and leading to alterations in synaptic 
neurotransmission. 
In this work, we have evaluated whether UPR was activated in 
vivo, in the brain of the knock-in mouse model carrying the 
R451C mutation in the endogenous NLGN3. We showed a 
selective increase of UPR markers levels in the cerebellum of 
the R451C mice, along with an increase in the frequency of 
the miniature excitatory currents in the Purkinje cells, that 
resulted to be UPR-dependent. 
At the same time, in order to find a strategy to rescue NLGN3 
folding and expression on the cell surface, we have generated 
and characterized a new cell-based model system that allowed 
studying NLGN3 protein trafficking. By using this system, we 
have screened an FDA-approved library of compounds for 
improving impaired protein folding. Among the compounds 
that have been tested, several members of the glucocorticoid 
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family showed efficacy in increasing mutant protein 
trafficking and restoring membrane localization.  
Collectively, our data indicated that the ER-retention of 
R451C NLGN3 in vivo, caused UPR activation and alterations 
of synaptic function in the cerebellum of a mouse model of a 
monogenic form of autism. Furthermore, we identified 
compounds improving NLGN3 folding and rescuing impaired 
trafficking. 
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Sommario 
Negli ultimi anni, un sempre maggior numero di mutazioni 
associate ai Disturbi dello Spettro Autistico (DSA) è stato 
rinvenuto in proteine coinvolte nella formazione e nella 
funzione delle sinapsi, come la famiglia delle proteine post-
sinaptiche Neuroligins (NLGNs). In particolare, la mutazione 
R451C in NLGN3 causa un parziale malripiegamento del 
dominio extracellulare della proteina, portando al suo 
trattenimento nel Reticolo Endoplasmatico (RE). L’accumulo 
nel RE della proteina R451C NLGN3, in vitro, causa 
attivazione dell’Unfolded Protein Response (UPR) ed è noto 
che l’espressione di questa proteina mutata porta ad alterazioni 
delle funzioni sinaptiche in diverse aree cerebrali. 
In questo lavoro abbiamo investigato l’attivazione dell’UPR in 
un modello murino di autismo che esprime in maniera 
endogena la proteina R451C NLGN3. I nostri dati mostrano 
attivazione di tale risposta cellulare in maniera specifica nel 
cervelletto dei topi R451C KI ed un aumento della frequenza 
della corrente eccitatoria spontanea nelle cellule del Purkinje, 
che è dipendente dall’attivazione della UPR. 
In parallelo, al fine di trovare una strategia per recuperare il 
corretto ripiegamento della proteina mutata e la sua 
espressione sulla superficie cellulare, abbiamo generato e 
caratterizzato un nuovo sistema modello cellulare che ci ha 
permesso di studiare il trafficking di R451C NLGN3 e di 
effettuare lo screening di una libreria di composti approvati 
dalla Food and Drug Administration americana. Tra i 
composti testati, diversi membri della famiglia dei 
glucocorticoidi sembravano in grado di aumentare il 
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trafficking e la localizzazione in membrana della proteina 
R451C NLGN3. 
Complessivamente, i nostri dati indicano che la mutazione 
R451C in NLGN3 porta all’attivazione dell’UPR in vivo, nel 
cervelletto di un topo modello di autismo, dove provoca 
alterazioni delle funzioni sinaptiche. Inoltre, abbiamo 
identificato un gruppo di composti in grado di ripristinare il 
corretto ripiegamento della proteina mutata e il suo traffico 
sulla superficie cellulare in un sistema modello in vitro. 
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General Introduction 
Autism Spectrum Disorders (ASDs) are a group of congenital 
developmental impairments of the central nervous system 
(Kawada et al., 2018), which are characterized by abnormal 
behaviour and communication skills emerging during 
childhood. Approximatively, 1% of children are affected by 
ADSs, with a male:female ratio of 4:1 (de la torre-Ubieta et 
al., 2016). 
The strong heterogeneity in both genetic and environmental 
risk factors associated with these syndromes makes difficult to 
understand their etiology. 
In the last years, more than five hundred genetic variants have 
been correlated with ASDs (Campisi et al., 2018). It is 
noteworthy that there are several affected cellular pathways 
among which the synaptic one. In fact, several susceptibility 
genes codify for synaptic proteins, highlighting that alterations 
in formation and function of the synapse play a major role in 
the development of psychiatric and neurological disorders 
(Taoufik et al., 2018; Ribeiro et al., 2018). Moreover, several 
environmental factors can act on this genetically vulnerable 
background to contribute to the ASDs pathogenesis (Li et al., 
2012; Campisi et al., 2018). 
Among the synaptic genes, a relevant role belongs to the 
Neuroligins (NLGNs) family of proteins. The post-synaptic 
NLGNs play a role in the stabilization and function of the 
synapse through the formation of a trans-synaptic bridge with 
pre-synaptic partner proteins of the Neurexins (NRXNs) 
family (Sudhof, 2008; Bang and Owczarek, 2013). NLGNs 
form a not-covalent homo- or heterodimer, whose interaction 
with NRXNs is regulated by several factors, such as 
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alternative splicing, glycosylation state and presence of Ca
2+
 
ions (Fabrichny et al., 2007). 
In humans, the NLGNs family comprises five members, 
whose genes are located on different chromosomes: NLGN1 
(3q26), NLGN2 (17p13), NLGN3 (Xq13), NLGN4 (Xp22.3) 
and NLGN5 (also known as NLGN4Y). 
The NLGNs show a non-overlapping distribution in the central 
nervous system, with NLGN1 at excitatory synapses and 
NLGN2 and NLGN4 at inhibitory synapses. Only NLGN3 
makes an exception, since it is expressed on both types of 
synapses (Bemben et al., 2015). Little is known about 
NLGN5, which is not expressed in rodents. 
Among the NLGNs genes, the highest number of ASDs-
associated mutations have been found in NLGN3 and NLGN4 
(Jamain et al., 2003; Talebizadeh et al., 2006; Yan et al., 
2005), though several mutations in ASDs patients have been 
recently mapped on NLGN1 gene (Nakanishi et al., 2017). 
The most characterized ASDs-associated mutation in the 
NLGNs family is a point mutation, resulting in a Cys 
substitution of an Arg residue at position 451 (R451C) in the 
extracellular protein domain of NLGN3. This mutation has 
been found in two Swedish brothers, one with autism and one 
with Asperger syndrome (Jamain et al., 2003). 
Studies conducted in vitro have shown that the R451C 
mutation affects protein folding and causes partial retention of 
NLGN3 in the Endoplasmic Reticulum (ER), leading to its 
degradation via proteasome (De Jaco et al., 2010). Moreover, 
it has been shown that the amount of R451C NLGN3 reaching 
the cell surface shows reduced binding to its pre-synaptic 
partner NRNX1β (Comoletti et al., 2004). 
The accumulation of misfolded proteins in the ER can 
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generate a cellular stress condition, which can trigger a 
complex signalling, the Unfolded Protein Response (UPR). 
This response activates transcription of target genes in the 
nucleus, with the aim to restore ER homeostasis (Chambers 
and Marciniak, 2014; Almanza et al., 2018). 
The UPR comprises three branches: PERK, IRE1 and ATF6. 
The first line of response is mediated by PERK, which inhibits 
general protein synthesis by direct phosphorylation of the 
translation factor eIF2α (McQuiston and Diehl, 2018). 
Moreover, IRE1, through its endonuclease activity, mediates 
the alternative splicing of the transcription factor XBP1, 
generating its active form (XBP1s) (Ni et al., 2018). 
Furthermore, in response to ER stress, ATF6 undergoes 
proteolytic cleavage, generating a transcription factor, ATF6n, 
which activates transcription of XBP1 and other UPR target 
genes (Hillary and FitzGerald, 2018). 
Besides the role played by UPR in pathological conditions, 
UPR targets have been recently implicated in the regulation of 
neuronal physiology (Martinez et al., 2018). For instance, it 
has been demonstrated that the axis IRE1-XBP1 plays a role in 
memory formation, through the transcriptional activation of 
BDNF (Martinez et al., 2016). Moreover, the regulation of 
protein synthesis mediated by PERK-eIF2α is implicated in 
synaptic plasticity (Di Prisco et al., 2014). 
Several studies have associated UPR activation with 
neurodegenerative diseases, such as Alzheimer’s, Parkinson’s 
and prion diseases (Mercado et al., 2016; Roussel et al., 2013), 
but little is known about the correlation between UPR and 
neurodevelopmental disorders. Only recently, Kawada and 
Mimori showed an up-regulation of UPR markers in the brain 
of mice born from VPA-injected mothers (Kawada and 
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Mimori, 2018). Valproic acid (VPA) administration during 
pregnancy is a known risk factor of ASDs pathogenesis in the 
offspring (Christensen et al., 2013). In the same year, Crider 
and colleagues found increased levels of UPR markers in the 
middle frontal cortex of ASDs patients (Crider et al., 2017). 
These data are indicating a possible role of ER stress and UPR 
activation in the pathogenesis of ASDs. In this context, our 
group has focused on studying UPR activation triggered by the 
R451C NLGN3 mutant protein. We have shown activation of 
all UPR branches in neuronal-like cells stably expressing 
R451C NLGN3 (Ulbrich et al., 2016). In particular, we have 
analysed both the activation state of the three UPR effectors 
and the expression levels of ER chaperones, such as BiP and 
GRP94, which are commonly up-regulated following UPR 
activation. Our work has correlated, for the first time, an 
ASDs-associated mutation to ER stress, putting the basis for 
further studies on the effects of UPR activation in vivo, in the 
context of the monogenic form of ASDs due to the mutation 
R451C in NLGN3. 
In 2007, the research group headed by prof. Südhof has 
generated a knock-in (KI) mouse carrying the R451C mutation 
in the endogenous NLGN3 gene (Tabuchi et al., 2007). This is 
considered a model of a monogenic form of ASDs, since it 
shows ASDs-like behaviours and alterations of synaptic 
neurotransmission in several brain areas, such as 
hippocampus, cerebral cortex and dorsal striatum (Tabuchi et 
al., 2007; Etherton et al., 2011; Martella et al., 2018). 
This KI mouse model is a useful tool for studying the effects 
of the human R451C NLGN3 mutation in vivo and to test 
possible treatment for the monogenic form of ASDs caused by 
it. Indeed, a crucial issue of ASDs is the lack of appropriate 
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cures, mostly due to its heterogeneity. Treatments developed 
so far act only at alleviating symptoms, such as aggressive 
behaviour and lack of attention. These pharmacological 
treatments are usually supported by psychological therapy, 
aiming at improving language and social communication. A 
better understanding of ASDs etiology would be the first step 
in developing targeted treatments solving the cause rather than 
the symptoms. 
In the last years, several studies aimed at developing 
treatments both for protein misfolding and attenuation of UPR 
activation using both in vitro and in vivo disease model 
systems. Some of them reached the stage of clinical trials in 
some cases of cancer and amyloidogenic diseases (Cortez and 
Sim, 2014; Valenzuela et al., 2016, 2018; Almanza et al., 
2018). 
In the context of misfolded proteins, the proteostatic function 
of chaperones, makes them a tempting therapeutic tool. 
Whereas molecular and chemical chaperones play a role at 
helping any other protein to fold, pharmacological chaperones 
are molecules specifically design to bind a protein of interest 
and induce its refolding (Cortez and Sim, 2014). 
On the other hand, in the last years many pharmacological and 
gene therapy approaches have been developed to modulate 
each UPR effector. At the moment, this research field is 
pointing at better understand the biochemical interaction 
between UPR factors and drug modulators, with the aim to 
generate more and more specific treatments (Almanza et al., 
2018). 
The above-mentioned strategies would represent valid 
approaches to contrast the effects of the R451C mutation in 
NLGN3, with the result of both restoring proper protein 
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localization and favouring protein escape from the ER. 
Moreover, reducing the ER overload, would alleviate UPR 
activation and mitigate its downstream effects on neuronal 
physiology and function. 
To conclude, finding molecules specifically helping protein 
folding would represent an avenue for treating diseases 
characterized by loss of function due to protein misfolding, or 
to diseases characterized by gain of function effects due to the 
retention of the misfolded protein in the ER. 
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Aims of the work 
Among the susceptibility genes whose mutations have been 
correlated to Autism Spectrum Disorders (ASDs), our interest 
is focused on the Neuroligins (NLGNs) family. NLGNs are 
postsynaptic cell-adhesion molecules interacting with a 
presynaptic partner of the Neurexins (NRXNs) family and 
supporting synapse formation and function. 
The most studied ASDs-associated mutation in NLGNs is the 
Arg451 to Cys (R451C) substitution in NLGN3. From in vitro 
studies, it is known that the mutation causes a misfolding of 
the extracellular protein domain, leading to a partial retention 
of NLGN3 in the Endoplasmic Reticulum (ER), to the 
activation of the Unfolded Protein Response (UPR) and its 
degradation through the proteasome. 
The generation of the knock-in (KI) mouse carrying the 
R451C substitution in the endogenous NLGN3 has allowed 
studying the effects of the mutation in vivo. The R451C KI 
mouse shows autistic-like behaviors and alterations of the 
synaptic neurotransmission in several brain areas, causing an 
excitatory/inhibitory imbalance, which is considered a 
hallmark of autism. 
In this thesis, we pursued two principal aims. The first aim 
was to better characterize the R451C KI mouse model. In 
particular, we aimed to further analyze both WT and R451C 
NLGN3 protein expression and degradation in vivo. Moreover, 
we sought to verify whether the mutant protein was retained in 
the ER and was able to induce UPR activation in a specific 
brain region of the R451C KI mouse.  
And whether UPR was activated, in one or more brain regions 
that we analyzed, we would evaluate electrophysiological 
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properties of those regions, since it is known from literature 
data that UPR can modulate synaptic transmission. 
The second aim of this thesis was to investigate for a strategy 
to restore correct protein folding of R451C NLGN3, in order 
to favor its escape from the ER and to rescue its proper 
localization on the cell surface and reduce the ER overload. To 
this purpose, we generated and characterized a new cell-based 
model system for screening a library of compounds approved 
by the American Food and Drug Administration (FDA) for 
improving protein trafficking and restoring proper protein 
localization and possibly lower UPR activation.  
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CHAPTER II: 
Screening of chemical compounds to restore the defective 
trafficking of R451C Neuroligin3 
 
Introduction 
The Endoplasmic Reticulum (ER) is the cellular compartment 
responsible for the synthesis of one-third of the proteome, 
through the action of ER-resident chaperones (Halperin et al., 
2014). Furthermore, several post-translational modifications 
take place in the ER, mostly represented by glycosylation and 
disulfide bond formation (Takayanagi et al., 2013). The 
folding and glycosylation state of proteins is monitored by the 
quality control system of the organelle, which allows only 
proteins correctly folded to undertake the secretory pathway; 
than otherwise would be shuttled for the ER-mediated 
degradation (ERAD) (Corazzari et al., 2017; Hebert and 
Molinari, 2007).  
To ensure these functions, the ER requires a fine homeostatic 
state to avoid perturbations that can lead to ER stress 
conditions. In case of stress, a highly conserved signaling 
pathway, the Unfolded Protein Response (UPR) is activated 
with the aim of restoring ER homeostasis by attenuating 
protein synthesis, enhancing protein folding capacity of the ER 
and protein degradation through the ERAD (Chambers and 
Marciniak, 2014).  
The accumulation of misfolded/unfolded proteins and UPR 
activation are hallmarks of several neurological and non-
neurological diseases, collectively called protein misfolding 
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disorders, such as Alzheimer’s, Parkinson’s, diabetes and 
cancer (Mercado et al., 2016; Corazzari et al., 2017). 
Recently, a growing interest is focused on developing small-
molecule drugs with chaperone-like activity, able to restore 
protein folding, by reducing the accumulation of misfolded 
proteins and re-establish normal trafficking to the appropriate 
subcellular localization.  
Numerous pharmacological and chemical chaperones have 
been tested both in vitro and in vivo in disease model systems 
and some of them reached the stage of clinical trials (Cortez 
and Sim, 2014). The well-known chemical chaperones, 
sodium 4-phenylbutyrate (4-PBA) and Trimethylamine N-
oxide dihydrate (TUDCA), have been shown to reduce ER 
stress in a mouse model of type II diabetes by increasing 
folding capacity (Ozcan et al., 2006). 4-PBA has also been 
tested in vivo, in mouse models of cerebral ischemic injury and 
spinal cord ischemia, showing positive effects on reducing ER 
stress and alleviating neurological damages (Qi et al., 2004; 
Mizukami et al., 2010). Among the neurological disorders, in 
the last years, several cellular pathways have been 
characterized for underlying Autism Spectrum Disorders 
(ASDs). Mutations in genes encoding for synaptic proteins 
have been studied at the molecular level for possible folding 
and trafficking impairments. Among these, the synaptic family 
of Neuroligins (NLGNs) proteins represent a group of proteins 
well-characterized (de la Torre-Ubieta et al., 2016; Baig et al., 
2017). NLGNs are post-synaptic cell-adhesion molecules, 
playing a role in synaptic organization and function, through 
the interaction with the pre-synaptic family of proteins 
Neurexins (NRXNs) and with scaffolding proteins (Südhof 
2008, 2017). 
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NLGN3 and NLGN4 were initially considered the most 
interested by ASDs-associated mutations. However, several 
mutations have been recently found in the NLGN1 gene 
(Nakanishi et al., 2017) 
It is noteworthy that most of these mutations impact on the 
folding of the protein extracellular domain, occurring in the 
ER, resulting in reduced trafficking of the mutant protein to 
the cell surface. The lack of these proteins at their proper 
localization, affect synaptic functions and cause behavioral 
defects (Ribeiro et al., 2018). 
Among the NLGNs mutations, the most studied is the 
substitution Arg451Cys (R451C) in NLGN3, which causes a 
local misfolding of the extracellular protein domain (De Jaco 
et al., 2010). The extent of the misfolding is sufficient to cause 
the retention of the mutant NLGN3 in the ER, leading to the 
activation of the UPR in PC12 Tet-on cell lines with inducible 
expression of NLGN3 (De Jaco et al., 2006; Ulbrich et al., 
2016). 
The Knock-In (KI) mouse carrying the R451C mutation in the 
endogenous NLGN3 gene, represents a model of a monogenic 
form of ASDs for its autistic-like behaviors and imbalance in 
the excitatory/inhibitory neurotransmission ratio (Tabuchi et 
al., 2007; Etherton et al., 2011). We have shown a drastic 
reduction in mutant NLGN3 protein levels in the whole brain 
during development and in the adulthood, supporting the effect 
of the mutation on protein stability in vivo (Trobiani et al., 
2018). The mutant protein is also retained in the ER in the 
whole brain of the R451C KI mouse and UPR is selectively 
activated in the cerebellum, where it modulates 
neurotransmission (Trobiani et al., 2018).  
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In this work, we aimed at generating an easy-to-use model 
system for the screening of chemical compounds with 
chaperone-like activity acting at improving protein folding in 
the ER in order to favor the escape of the mutant NLGN3 from 
the organelle, restoring its physiological expression to the cell 
surface and alleviating UPR.  
This would represent a possible strategy to treat the 
monogenic form of ASDs caused by the R451C mutation in 
NLGN3, but it would be potentially useful for other protein 
misfolding diseases due to the retention of mutant proteins in 
the ER. 
  




Generation of HEK293 cell lines expressing 
truncated and fluorescent NLGN3 
Previous studies showed alterations of the full-length R451C 
NLGN3 protein trafficking through the secretory pathway. 
Indeed, the mutant protein was shown to be retained in the ER 
failing to reach the cell surface (De Jaco et al., 2006, 2010). 
We have generated a new cell-based model system to study 
NLGN3 trafficking by using HEK293 cell lines stably 
expressing a truncated form of NLGN3 made of the 
extracellular protein domain, lacking the transmembrane and 
intracellular protein domains, and C-terminally fused to the 
Venus Fluorescent Protein (Giepmans et al., 2006) (Fig. 1A).  
These cell lines produce a fluorescent NLGN3, either WT or 
R451C, that is secreted by the cell, allowing to evaluate 
protein trafficking by measuring fluorescence levels in the cell 
culture medium. We have generated several clones expressing 
the truncated protein forms that were characterized for the 
levels of fluorescence in the medium and the levels of protein 
expression (Fig. 1B).  
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Figure 1. Generation of HEK293 cell lines expressing 
truncated and fluorescent NLGN3 
A. Schematic representation of the vectors encoding for the 
NLGN3 truncated and fluorescent protein forms. 
B. Fluorescence levels (RFU) and representative western blot 
of cell medium and lysates from three stably transfected clones 
(mean ± SEM; n= 4). 
 
R451C NLGN3-Venus shows reduced secretion and 
increased degradation rate 
To further characterize the newly generated cell-system, we 
compared basal levels of fluorescence in the medium of WT 
and R451C NLGN3-Venus selected clones and found a 
consistent and significative reduction of the R451C NLGN3-
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Venus protein secretion (~50%) compared to the WT protein 
(Fig. 2A), that was also confirmed by western blot analysis 
(Fig. 2B). To assess if the reduced levels of the R451C 
NLGN3-Venus are due to degradation through the ERAD, as 
it was previously shown for the full-length protein (De Jaco et 
al., 2010), we blocked the proteasome with the inhibitor 
MG132 and observed the accumulation of the mutant protein 
in the cell, not detectable for the WT protein (Fig. 2C-D). 
 
Figure 2. Characterization of WT and R451C NLGN3-
Venus selected clones 
A. Fluorescence levels (RFU) in medium from WT and 
R451C NLGN3-Venus expressing cells (mean ± SEM; n= 12; 
P<0.001; Mann Whitney test). 
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B. Representative western blot of NLGN3-Venus levels in 
medium from WT and R451C expressing cells. 
C. NLGN3-Venus levels in the medium from WT and R451C 
expressing cells after treatment with MG132 or in untreated 
condition. 
D. Densitometric analysis of NLGN3 protein levels in the 
lysates after treatment with MG132, normalized and compared 
(for each genotype) to untreated control condition (mean ± 
SEM; n= 4; one-way ANOVA *P< 0.05). 
 
ER-retained R451C NLGN3-Venus activates UPR 
Previous work from our group showed the activation of all 
three branches of the UPR in the PC12 Tet-On cell system 
with inducible expression of R451C NLGN3 (Ulbrich et al., 
2016). Thus, we studied UPR activation in the newly-
generated cell system by investigating ATF6 activity by 
luciferase assay. HEK293 cells expressing either WT or 
R451C NLGN3-Venus were transfected with a reporter using 
the Firefly luciferase gene under the control of the ERSE (ER 
stress sequence elements), found in the promoter of ATF6-
target genes. Co-transfection with a Renilla luciferase reporter 
has been used to assess transfection efficiency. Cells 
expressing R451C NLGN3-Venus showed significantly higher 
activation levels of ATF6 compared to WT (Fig. 3). 
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Figure 3. UPR activation in HEK293 NLGN3-Venus cells 
ATF6 activation in HEK293 cells expressing either WT or 
R451C NLGN3-Venus, shown as ratio Firefly/Renilla 
luciferases normalized and compared to WT condition (mean 
± SEM; n= 6; Student’s t-test ***P< 0.001). 
 
4-PBA improves NLGN3-Venus trafficking 
It is notable that known chemical chaperones, such as 4-PBA, 
can stabilize protein folding and increase protein trafficking in 
vitro (Uggenti et al., 2016). We treated WT and R451C 
NLGN3-Venus expressing cells with 4-PBA (500 µM) and 
measured fluorescence levels in the medium.  We detected a 
significant increase of fluorescence for the mutant protein, 
indicating a positive effect of 4-PBA on improving defective 
protein trafficking and secretion (Fig. 4). However, this 
increase was observed also in the medium of the cells 
expressing the WT protein, denoting a generalized effect of 
this chemical chaperone on protein folding. 
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Figure 4. Effects of 4-PBA on WT and R451C NLGN3-
Venus expressing cells 
Fluorescence levels (RFU) after treatment with 4-PBA (500 
µM), normalized and compared (for each genotype) to 
untreated control condition (mean ± SEM; n= 12; one-way 
ANOVA *P<0.05 ***P<0.001). 
 
Screening of an FDA-approved library of 
compounds 
A library of 2662 compounds was screened for enhancing 
secretion of mutant R451C NLGN3-Venus protein. All the 
compounds were previously approved by the American Food 
and Drugs Administration (FDA) for treatment of a variety of 
neurological and non-neurological diseases.  
The screening was performed at a concentration of 2 µM on 
HEK293 cells expressing R451C NLGN3-Venus. The 
fluorescence in the medium was measured after 60 hours from 
treatment, to allow the mutant protein to accumulate to levels 
detectable by a fluorimeter. From this initial screening, we 
selected 12 compounds, which showed a 2-fold increase in the 
fluorescence levels in comparison to the untreated condition 
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(Fig. 5A). It is noteworthy that most of these compounds 
belonged to the glucocorticoid family, which is known to 
increase the levels of ER-resident chaperones (Das et al., 
2013). 
See supplementary Fig. 1 for a more detailed list of positive 
compounds. 
To confirm data obtained in this first screening and to exclude 
that some contaminants were present in the library and were 
interfering with the results, we performed a second screening 
using a new batch of each compound. However, we chose only 
5 of them, 3 glucocorticoids (Prednisolone sodium phosphate, 
Desonide, Alclometazone dipropionate) and 2 belonging to 
other chemical families (Quinestrol, Phenytoin sodium) (Table 
1) for this further characterization. We tested them on both 
WT and R451C NLGN3-Venus cells and DMSO was used as 
vehicle control condition. Only treatments with 
glucocorticoids showed to significantly increase trafficking of 
the mutant protein in comparison to control untreated 
condition, while Quinestrol and Phenytoin sodium had no 
effect, such as DMSO (Fig. 5C). Glucocorticoids had no effect 
on the WT NLGN3-Venus (Fig. 5B), indicating a specific 
effect of the compounds only on the mutant form of the 
protein.  
The significant increase in protein secretion was confirmed by 
western blot analysis on the cell media (Fig. 6A). It is 
noteworthy that the amount of NLGN3-Venus protein was 
unchanged in cell lysates after treatment (Fig. 6B). This was 
indicating that treatment didn’t affect protein synthesis but 
rather induced a higher proportion of R451C NLGN3-Venus 
protein to be released in the cell medium. 




Selected compounds that resulted positive from the first 
screening. The amount of increased fluorescence in the cell 
medium of R451C NLGN3-Venus expressing cells and the 
chemical class to which the single compounds belong are 
indicated. 
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Figure 5. Screening of an FDA-approved library of 
compounds 
AD: alclometazone dipropionate; BA: betamethasone acetate; 
CBX: carbenoxolone sodium; D: desonide; DES: 
desoxymetasone; EH: ethylnorepinephrine hydrochloride; IA: 
isoflupredone acetate; MH: milnacipran hydrochloride; PA: 
phenylethyl alcohol; PS: phenytoin sodium; PSP: prednisolone 
sodium phosphate; Q: quinestrol 
A. Fluorescence levels (RFU) in the medium of HEK293 
R451C NLGN3-Venus treated with indicated compounds, 
normalized and compared to untreated control condition 
(CTRL) (mean ± SEM; n= 4; one-way ANOVA ***P<0.001). 
B. Fluorescence levels (RFU) in the medium of HEK293 
expressing WT NLGN3-Venus treated with selected 
compounds or with vehicle control (DMSO), normalized and 
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compared to control condition (CTRL) (mean ± SEM; n= 7; 
one-way ANOVA). 
C. Fluorescence levels (RFU) in the medium of HEK293 
expressing R451C NLGN3-Venus treated with selected 
compounds or with vehicle control (DMSO), normalized and 
compared to control condition (CTRL) (mean ± SEM; n= 7; 
one-way ANOVA **P<0.01). 
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Figure 6. Quantification of NLGN3-Venus protein after 
treatment 
AD: alclometazone dipropionate; D: desonide; PS: phenytoin 
sodium; PSP: prednisolone sodium phosphate; Q: quinestrol 
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A. Representative western blot of NLGN3-Venus levels in cell 
lysates and in medium from WT and R451C expressing cells 
after treatment with indicated compounds  
B. Densitometric analysis of NLGN3-Venus levels in cell 
medium from WT and R451C expressing cells after treatment 
with indicated compounds, normalized and compared to 
CTRL condition (mean ± SEM; n= 4; one-way ANOVA 
*P<0.05 **P<0.01).  
C. Densitometric analysis of NLGN3-Venus levels in cell 
lysates from WT and R451C expressing cells after treatment 
with indicated compounds, normalized and compared to 
CTRL condition (mean ± SEM; n= 4; one-way ANOVA). 
 
Selected compounds improve trafficking of full- 
length R451C NLGN3 
Compounds selected for enhancing trafficking of the truncated 
and fluorescent form of NLGN3 were then tested on cells 
expressing the full-length form of the protein. HEK293 cells 
were transiently transfected with the pcDNA3.1 vector 
encoding for R451C NLGN3 full-length and co-localization 
staining with the ER marker calreticulin was analyzed by 
confocal microscopy (Fig. 7A) in order to evaluate the exit of 
the mutant R451C protein from the ER. The effect of the 
compounds to decrease the amount of co-localization was used 
as a parameter of their activity. HEK293 cells transiently 
transfected with WT NLGN3 full-length normally expressed 
on the cell surface were used as control. As expected, this 
condition showed a significant lower co-localization with 
calreticulin in comparison to cells expressing mutant NLGN3 
(Fig. 7B). R451C NLGN3 expressing cells were treated with 5 
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of the selected compounds and co-localization with 
calreticulin was assessed 48 h after treatment. We considered 
as positive those compounds able to decrease all three 
coefficients calculated. It was confirmed that Alclometazone 
dipropionate and Prednisolone sodium phosphate, resulted the 
most effective in improving trafficking of both the truncated 
and full-length R451C NLGN3 mutant forms. The remaining 
compounds seem not to have any effect on decreasing ER-
localization of the full-length mutant protein (Fig. 7C-D-E). 
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Figure 7. Compounds effect on localization of full length 
NLGN3 
AD: alclometazone dipropionate; D: desonide; PS: phenytoin 
sodium; PSP: prednisolone sodium phosphate; Q: quinestrol 
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A. Representative confocal images of NLGN3 (red) and 
Calreticulin (green) staining in HEK293 cells transfected with 
either WT or R451C NLGN3 treated with selected compounds 
(scale bar 1µm).  
B. Quantification of NLGN3-calreticulin co-localization in 
cells expressing either WT or R451C NLGN3, normalized and 
compared to WT condition. Pearson’s coefficient (PC) and 
both Mander’s overlap coefficients M1 and M2 were 
measured (mean ± SEM; n= 54 cells/3 independent 
experiments; one-way ANOVA **P<0.01 ***P<0.001). 
C. Pearson’s coefficient measured in cells expressing either 
WT or R451C NLGN3 and treated with indicated compounds, 
normalized and compared to CTRL condition (mean ± SEM; 
n= 50 cells/3 independent experiments; one-way ANOVA 
**P<0.01 ***P<0.001). 
D. Mander’s overlap coefficient M1 analysis in cells 
expressing either WT or R451C NLGN3 and treated with 
indicated compounds, normalized and compared to CTRL 
condition (mean ± SEM; n= 50 cells/3 independent 
experiments; one-way ANOVA **P<0.01 ***P<0.001). 
E. Analysis of Mander’s overlap coefficient M2 in cells 
expressing either WT or R451C NLGN3 and treated with 
indicated compounds, normalized and compared to CTRL 
condition (mean ± SEM; n= 55 cells/3 independent 
experiments; one-way ANOVA *P<0.05 **P< 0.01). 
 
Compounds fail to lower UPR activation induced 
by full length R451C NLGN3  
We evaluated the effect of the compounds on alleviating UPR 
activation due to the retention of the full length R451C 
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NLGN3 in the ER. To this purpose, we used the UPR reporter 
that measures the activation of the ATF6 branch. HEK293 
cells were transiently transfected with pcDNA3.1 expressing 
full length NLGN3, either WT or R451C, and with the 
luciferase reporter vectors previously used (Fig. 3). Cells 
expressing R451C NLGN3 were treated with 5 selected 
compounds and luciferase activity was measured, in each 
condition, 48 h after treatment. HEK293 cells expressing WT 
NLGN3 represented the control condition. The treatment with 
the compounds failed to decrease the activation of ATF6 in 
cells expressing R451C NLGN3 comparing to untreated 
condition (Fig. 8).  
 
Figure 8. Effects of compounds on UPR activation 
AD: alclometazone dipropionate; D: desonide; PS: phenytoin 
sodium; PSP: prednisolone sodium phosphate; Q: quinestrol 
Firefly/Renilla luciferases activities in HEK293 cells 
expressing either WT or R451C NLGN3 and treated with 
indicated compounds, compared to CTRL condition (mean ± 
SEM; n= 5; one-way ANOVA).  
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Discussion 
In the last years, the research field on diseases correlated to the 
accumulation of misfolded proteins has been greatly 
expanding. Collectively called protein-misfolding diseases, 
they include common neurological and non-neurological 
disorders, such as Alzheimer’s, Parkinson’s, Cystic Fibrosis, 
Cancer and Diabetes (Koss and Platt, 2017; Sarvani et al., 
2017; Scheper and Hoozemans, 2016). In these disorders, the 
common underlying mechanism is represented by the 
accumulation of misfolded proteins. The ER is specialized in 
recognizing and retaining not properly folded proteins that 
undertake the secretory pathway. This might result in a double 
effect: a loss-of-function due to the mis-localization of the 
protein, and the accumulation of the protein in the organelle 
leading to a toxic gain-of-function and in most cases to ER 
stress conditions. In this contest, the research for small 
molecules facilitating protein folding and their escape from the 
ER is becoming of growing interest. Chemical chaperones are 
useful tools in helping protein folding, but their lack of 
specificity limits their potential as therapeutics. On the other 
hand, pharmacological chaperones have a higher specificity, 
being designed to bind a selected protein (Cortez and Sim, 
2014). 
Our work focused on the biological effects caused by the 
Arg451 to Cys substitution (R451C) in the extracellular 
domain of the post-synaptic protein Neuroligin3 (NLGN3). 
This mutation, found in patients with ASDs, causes the 
retention of the protein in the ER and its loss at the synapse, 
where it plays a crucial role as a cell-adhesion molecule (Baig 
et al., 2017). Our recent work established the first evidence 
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between the retention of the R451C NLGN3 in the ER and the 
activation of UPR in vitro (Ulbrich et al., 2016). Moreover, 
mice carrying the R451C mutation in the endogenous NLGN3 
gene show altered neurotransmission in several brain areas 
correlated to ASDs (Tabuchi et al., 2009; Etherton et al., 2001; 
Trobiani et al., 2018). However, it is not clear if those 
alterations are due to the loss of NLGN3 proper localization 
on the cell surface, or if it is a consequence of the ER stress 
condition due to the retention of the protein in the organelle 
(Trobiani et al., 2018). In fact, it is possible that, in almost 
completely absence of NLGN3 on the cell surface, the pre-
synaptic partner NRXN1β associates with other ligands, thus 
inducing a gain-of-function. Besides, this hypothesis does not 
exclude the possibility that the UPR, induced by the ER-
retention of R451C NLGN3, represents an additional factor 
participating to the gain-of-function phenotype. 
The effect of restoring proper protein localization to rescue 
phenotype, has been shown by Mei and colleagues in the 
Shank3:Cre conditional Knock-In (KI) mouse, a model of 
ADSs  (Mei et al., 2016). Untreated mice showed a phenotype 
characterized by molecular, electrophysiological and 
behavioural alterations. Treatment with Tamoxifen activates 
the Cre-recombinase and re-establishes expression of Shank3 
at the post-synaptic site, allowing an almost complete recovery 
of the phenotype. Therefore, restoration of proper protein 
expression and cellular disposition might represent a strategy 
to treat diseases characterized by protein mis-localization. 
In this prospective, helping the mutant R451C NLGN3 to exit 
the ER would be beneficial in two ways: restoring proper 
protein localization for its function, and alleviating the 
overload of the ER, reducing ER stress and UPR activation.  
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We generated stable cell lines expressing a truncated form of 
either WT or R451C NLGN3, tagged with the fluorescent 
protein Venus and demonstrated that their trafficking was 
impaired similarly to what was previously shown for the full- 
length form of the protein (De Jaco et al., 2006, 2010). We 
report a ~50% reduction of R451C protein release compared to 
the WT, increased protein levels following the inhibition of 
proteasome activity and activation of the UPR. Our cell model 
system responded to the treatment with 4-PBA, as showed by 
the increase of protein trafficking for both WT and R451C 
NLGN3-Venus proteins, suggesting a generalized effect of 4-
PBA on all proteins passing through the ER. However, our 
interest was focused on identifying compounds selective for 
the mutant R451C NLGN3 form.  
We screened a library of compounds, approved by the FDA 
for treatment of a variety of other diseases. The screening used 
a concentration 250-fold lower than the one used for 4-PBA 
and closer to normally used pharmacological concentrations. 
We found 12 compounds able to enhance R451C NLGN3-
Venus trafficking, doubling its amount in the cell medium. It 
is noteworthy that those compounds had no effect on 
trafficking of the WT NLGN3-Venus. Two out of the three 
compounds which resulted the most effective on the truncated 
NLGN3-Venus, Alclometazone dipropionate and Prendisolone 
sodium phosphate, showed a specific activity in reducing the 
retention of the full-length protein in the ER.  
Unfortunately, none of the compounds showed an effect at 
reducing the activation of the ATF6 branch of the UPR caused 
by the retention of the full-length R451C NLGN3 in the ER. 
However, it is possible that they modulate other branches of 
this cellular response or that the amount of mutant NLGN3 
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escaping from the ER in response to treatment, is not enough 
to reduce ER stress and UPR activation. Although, the 
selective effect on the mutant NLGN3, with no effect on the 
WT form, is indicating that the compounds were not affecting 
the generalized protein trafficking through the secretory 
pathway. Instead, they were improving protein folding, 
probably by increasing levels of ER chaperones (Das et al., 
2013; Fujii et al., 2006). It has been shown both in vitro and in 
vivo, that the administration of exogenous glucocorticoids, was 
able to increase levels of ER chaperones, such as Calreticulin, 
BiP and Hsp70, and induce the escape of an ER-retained 
protein from this organelle (Das et al., 2013; Duzgun et al., 
2013; Fujii et al., 2006; Nair et al., 2018). Moreover, it has 
been shown that dexamethasone, a synthetic glucocorticoid 
used in clinic, has a role in modulating the half-life of CFTR 
by attenuating its interaction with a ubiquitin E3 ligase in vitro 
(Caohuy et al., 2009). 
Glucocorticoids mediate their effects by binding the 
intracellular receptor GR, which translocates to the nucleus 
and activates transcription of target genes, by binding specific 
glucocorticoids response elements (GREs) (Meijsing 2015). 
By this way, glucocorticoids regulate several cellular 
processes. 
In this contest, our findings strongly suggest a role for 
glucocorticoids in the regulation of protein folding and 
trafficking and establish a new prospective for treatment of 
misfolding protein diseases and for the monogenic form of 
autism due to the R451C substitution in the synaptic protein 
NLGN3. 
Based on these data, in the next future, we aim at elucidating 
the mechanism of action of glucocorticoids for improving 
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protein trafficking in our model systems. Moreover, we want 
to investigate the ability of glucocorticoids at increasing 
NLGN3 protein expression in vivo. Besides, we want to assess 
the activity of these compounds on other mutant proteins, in 
order to verify whether this effect is specific for the R451C 
NLGN3 or is common to ER-retained proteins that are not 
structurally correlated. 
  









Truncated rat NLGN3 was generated by introducing a stop 
codon right after the residue Tyr640 in the cDNA encoding for 
full-length NLGN3 either WT or carrying the mutation 
Arg451Cys (R451C). The cDNAs were subcloned into a 
vector encoding an N-terminal FLAG octopeptide and were 
additionally tagged at the C-terminus with Venus, an analog of 
the Green Fluorescent protein. 
 
Selection of stable clones of HEK293 cells 
expressing truncated NLGN3-Venus  
pcDNA3.1 plasmid, encoding truncated NLGN3-Venus either 
WT or R451C, has been used for transfecting HEK293 cells, 
using polyethylenimine (PEI) procedure (Sigma-Aldrich). 
Transfected cells were cultured in selective medium composed 
by DMEM (Dulbecco’s Modified Eagle’s Medium, Sigma), 
5% Fetal Bovine Serum (FBS, Sigma-Aldrich) and 500 µg/ml 
Geneticin (G418, Corning). Resistant cells have been plated at 
clonal density in 96-well plate and expanded to obtain clones, 
which were screened for NLGN3 protein expression by 
quantifying fluorescence levels in the culture medium and by 
Western blot on both cell lysates and medium. Stable cell lines 
are maintained in medium containing 500 µg/ml G418 at 37°C 
and 5% CO2. 
The proteasome-inhibitor MG132 (Z-Leu-Leu-Leu-al, #C2211 
Sigma-Aldrich) at concentration of 2.5 µM was added in the 
medium for the last 48 h of culture before harvesting. 
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Luciferase assay 
To assess ATF6 activation, 800.000 HEK293 cells were 
seeded in a 6-well plate. At 24 h after plating, cells were 
transfected with 2 µg of total DNA according to the 
Lipofectamine2000 protocol (Thermo Fisher Scientific). For 
HEK293 cells stably expressing NLGN3-Venus, total DNA 
was represented by two vectors: pATF6(5 x)-Luc (Firefly) and 
pTK (Renilla) in a 50:1 ratio (Davies et al., 2009). Otherwise, 
besides these two reporter vectors, pcDNA3.1 expressing full 
length NLGN3, either WT or R451C, was added to the 
transfection mix. Moreover, in the latter case, 3 h after 
transfection, HEK293 cells expressing R451C NLGN3 were 
treated with selected compounds at 2 µM concentration. 
Transfection was carried out for 48 h, then cells were 
harvested and activity of both luciferases was assessed by the 
Dual-luciferase Reporter Assay kit (Promega) and detected by 
the Glomax multi+ detection system (Promega). 
 
Treatment with chemical chaperones  
HEK293 cells expressing either WT or R451C NLGN3-Venus 
were plated at a density of 600.000 cells in 24-well plate. 24 h 
after seeding, medium was changed to Optimem (Gibco) and 
sodium 4-phenylbutyrate (4-PBA, Sigma-Aldrich) was added 
at the concentration of 500 µM in the cell culture medium. 
For the screening of the FDA-approved compounds, 75.000 
cells from both lines have been plated in 96-well plate, in 150 
µl Optimem medium added with 2% FBS.  
The 2662 compounds of the library were dissolved in 10% 
DMSO (Sigma-Aldrich) and used at final concentration of 2 
µM. Compounds were added in the cell culture medium 24 
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hours after seeding and fluorescence levels were measured 
after 60 h of treatment. Cells treated with 0,3% DMSO were 
used as vehicle control. 
 
Quantification of protein secretion by fluorimetric 
measurements 
To evaluate NLGN3-Venus protein trafficking, 100 µl of 
medium from cells either untreated or treated with selected 
compounds was transferred in a black 96-well plate and 
fluorescence was measured by a fluorimeter (excitation 
wavelength 485 nm, emission wavelength 535 nm). 
 
Preparation of protein samples 
Lysates of HEK293 cells were obtained using lysis buffer (150 
mM NaCl, 10 mM Tris pH 8.0, 0.5% Nonidet P40) 
supplemented with proteases inhibitor cocktail (Sigma-
Aldrich). Lysis was performed for 15 min on ice, followed by 
centrifugation at 17000 g for 15 min at 4°C. Protein 
concentration in the samples was determined by the Bradford 
assay. 
 
SDS-PAGE and Western blot 
Equal amount of cell medium or 30 µg of cell lysate from 
NLGN3-Venus (WT or R451C) cells were subjected to SDS-
PAGE (10% v/v polyacrylamide gel) in running buffer (25 
mM Tris pH 8.3, 0.19 M Glycine, 0.1% Sodium dodecyl 
sulfate) and transferred to PVDF membrane (Merck-Millipore) 
in transfer buffer (25 mM Tris pH 8.3, 0.19 M Glycine, 10% 
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Methanol). The membrane was blocked with 5% w/v non-fat 
milk in PBS (2.68 mM KCl, 1.47 mM KH2PO4, 0.137 M 
NaCl, 10.16 mM Na2HPO4) and stained with anti-FLAG M2 
(1:1000, mouse, Sigma-Aldrich #F3165) or anti-β-Actin 
(1:1000, mouse, Millipore #MAB1501) primary antibodies 
diluted in PBS containing 1% BSA (Sigma-Aldrich). HRP 
(horseradish peroxidase)-conjugated anti-mouse (goat, Sant 
Cruz Biotechnologies #SC-2005) secondary antibody was 
diluted 1:10000 in 5% milk in PBS. All the incubations were 
performed for 1 h at room temperature. The HRP signal has 
been detected by using ECL (HyGLO, Denville Scientific 
Inc.) and visualised by a ChemiDoc system (BioRad). 
 
Immunocytochemistry 
HEK293 cells (100.000 cells/well) were plated on glass 
coverslips coated with 0.5 mg/ml poly-D-lysin (Sigma-
Aldrich) in 24-well plates. Cells were transfected with cDNA 
NLGN3 full-length either WT or R451C using the calcium 
phosphate method and treated with selected compounds for 48 
h. Untreated cells cultured in the same conditions were used as 
control. Cells were washed with PBS and fixed with 4% 
paraformaldehyde (PFA, Sigma-Aldrich) for 20 minutes at 
room temperature, followed by fixation with pre-chilled 
methanol (Sigma-Aldrich) for 15 minutes at -20°C. 
The blocking step was performed for 1 h at room temperature 
using a solution containing 2% normal sheep serum (NSS), 
0.1% Triton-X100, 0.02% sodium azide in PBS. The same 
solution has been used for diluting primary and secondary 
antibodies. Anti-FLAG (1:5000, Rabbit, Sigma-Aldrich 
#F7425) and anti-calreticulin (1:500, Mouse, Enzo ADI-
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SPA601) were incubated in combination, overnight at 4°C, 
while fluorescent secondary antibodies Cy3-anti-rabbit 
(donkey, Jackson Immuno Research #711-165-152) and Alexa 
Fluor 488-anti-mouse (donkey, Jackson Immuno Research 
#715-545-151) were diluted 1:500 and incubated 1 h at room 
temperature. Nuclei were stained with Hoechst (Thermo 
Fisher Scientific) 1:1000 in PBS for 10 min. Fluorescent 
signal was detected by confocal microscope (Zeiss) at 63x 
magnification and co-localization analysis was obtained on Z-
stack images using the JACoP plugin of the NIH software 
ImageJ as previously described (Bolte and Cordelières, 2006). 
Pearson’s correlation coefficient and Mander’s overlap 




All experiments were performed at least three times on 
independent biological samples, as indicated in the figure 
legends. Student’s t-test, Mann Whitney test and one-way 
ANOVA with Bonferroni multiple comparison test were used 
for statistical analysis by using Prism5 (Graph-Pad 5 Software 
Inc.): *p<0.05, **p<0.01, ***p<0.001. 
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List of the top 69 compounds selected from the screening. 
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General conclusions and perspectives 
Several neurological and non-neurological diseases can be 
ascribed to mutations causing alterations of the three-
dimensional structure of the involved proteins (Mercado et al., 
2016; Corazzari et al., 2017). According to the severity of the 
misfolding, proteins can be retained in the ER and degraded. 
The consequence of this process is a loss-of-function, due to 
the lack of proper protein localization. However, the 
accumulation of misfolded proteins in the ER can induce a 
gain-of-function, due to the activation of the UPR (Almanza et 
al., 2018). Indeed, besides its role in responding to stress and 
re-establishing ER homeostasis, UPR plays a role in 
modulating several aspects of cell physiology. This is of 
particular interest in the brain, where it has been demonstrated 
that UPR can regulate synaptic function (Di Prisco et al., 
2014; Nosyreva and Kavalali, 2010). 
In this contest, a consistent field of research is focusing on 
developing treatments for improving protein folding therefore 
alleviating ER stress. 
Our interest is focused on the biological effects of the ASDs-
associated mutation R451C in the synaptic protein NLGN3. 
This mutation maps in the extracellular domain, causing a 
local misfolding of this protein region, which leads to an 
almost complete retention of NLGN3 in the ER in several 
cellular model systems (De Jaco et al., 2010; Ulbrich et al., 
2016). 
In my PhD thesis I have conducted two strictly correlated 
studies, both focused on the R451C mutation. The first 
concerned the effects of the mutation in vivo and the second 
relates to the development of an in vitro approach for studying 
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strategies to rescue NLGN3 folding defects caused by the 
mutation.  
The in vivo approach used the knock-in (KI) mouse model 
endogenously expressing the R451C NLGN3 protein (Tabuchi 
et al., 2007). My work has demonstrated that the R451C 
mutation induced protein instability and ER-retention in the 
total brain of the KI mouse, similarly to what has been 
demonstrated in vitro, causing an increase in its degradation 
rate in comparison to the parental WT strain (Trobiani et al., 
2018). This is the first study that analyzed the expression of 
the mutant protein during development. Moreover, my work 
showed that the effects caused by the mutation were detectable 
already during development at the embryonic stage E18, 
supporting the role of NLGN3 in synapses assembly and 
maturation (Williams et al., 2010). Interestingly, we observed 
UPR activation selectively in the cerebellum both at 
embryonic and adult stages. Remarkably, we have shown that 
it caused alterations of the synaptic functions, influencing the 
release of glutamate from the pre-synaptic terminal (Trobiani 
et al., 2018). This result fits with the current literature 
proposing a role for the UPR in regulating physiological 
function of the nervous system (Di Prisco et al., 2014; 
Martinez et al., 2016, 2018). 
The selective impairment of the cerebellum rather than other 
brain regions can be explained by the higher sensitivity of this 
region to stress (Kosuge et al., 2006; Sun et al., 2013). 
Therefore, our data provide evidence for a gain-of-function 
effect of the R451C mutation in vivo and establish a link 
between UPR and the ASDs phenotype. Moreover, our results 
strengthen the importance of dysfunction of the cerebellum in 
neurodevelopmental disorders. In fact, the implication of the 
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cerebellum in the pathogenesis of ASDs has been highlighted 
by both clinical and preclinical studies. Moreover, several 
genes whose mutations have been associated to ASDs are 
highly expressed in the cerebellum, such as the Neuroligins 
(Tsai, 2016). 
The second aim of my work was focused on developing an in 
vitro approach, to fish a commercial library for chemical 
compounds improving mutant NLGN3 protein folding. We 
have generated cell lines expressing a truncated and 
fluorescent form of NLGN3 consisting of the extracellular 
domain, protein region where most of the autism-linked 
mutations are found.   We have used this system to study the 
trafficking of R451C NLGN3, however in the future this 
strategy could be applied for studying other autism-linked 
mutations or to study the R451C homologous mutations in 
acetylcholinesterase, butyrylcholinesterase or thyroglobulin 
(De Jaco et al., 2006, 2012). 
The screening of a library of chemical compounds, using this 
newly generated cell system, identified several members of the 
glucocorticoid family showing activity in rescuing the 
trafficking of R451C mutant protein and reducing its ER-
retention. Although these glucocorticoids do not influence the 
ATF6 branch of the UPR, this is not excluding that they might 
act on other branches of this response or through a different 
mechanism. However, it is noteworthy that these 
glucocorticoids showed an effect only on the mutant form of 
the protein, with no effect on the WT form of NLGN3. This is 
indicating that their action is not generalized on all proteins 
undertaking the secretory pathway, but that it is specific of 
misfolded ones. This might be due to the previously 
demonstrated ability of glucocorticoids to increase levels of 
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ER chaperones in conditions of ER stress (Das et al., 2013). In 
this case, chaperones would have an effect only on the 
misfolded protein rather than on the WT, which is already 
correctly folded. 
Considering the data I have obtained so far, the future 
prospective will investigate the role of glucocorticoids in 
regulating protein trafficking in order to reveal the mechanism 
of action. Indeed, it is known that they can increase levels of 
ER chaperones and, in some cases, modulating the interaction 
between a ubiquitin E3 ligase and its protein target (Duzgun et 
al., 2013; Caohuy et al., 2009). 
Afterward, it would be interesting to test their efficacy in vivo, 
by determining whether the treatment improve R451C NLGN3 
protein stability in the brain of the KI mouse model. 
Moreover, glucocorticoids could be tested for alleviating the 
functional alterations induced by the UPR in the cerebellum. 
In fact, a direct interaction between glucocorticoids, their 
receptor and members of the UPR cascade has been previously 
demonstrated (Duzgun et al., 2013; Mihailidou et al., 2016). 
In order to generalize the effect of these compounds on acting 
on protein folding, it would be necessary to investigate the 
activity of glucocorticoids on other misfolded proteins whose 
mutations induce ER-retention, but that are structurally not 
correlated to NLGN3, such as Caspr2 (Falivelli et al., 2012). 
This would elucidate whether they are potentially useful for 
any ER-retained locally misfolded protein such as the R451C 
mutation in NLGN3. 
To conclude, our work is part of a new and intriguing field of 
research, which aims to find a possible treatment for diseases 
correlated with protein misfolding, most of which have been 
untreatable so far. Moreover, it supports the contribution of the 
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synaptic pathway in the etiology of ASDs. In fact, we have 
shown that a decreased trafficking of a synaptic protein and its 
retention in the ER, due to a misfolding mutation, impairs 
synaptic transmission in a specific brain area. Our work 
contributes to a better understanding of the molecular 
mechanisms underlying the ASDs pathogenesis. 
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